

MusclePharm Corp  
Form 8-K  
January 06, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report: December 30, 2015**

**(Date of earliest event reported)**

**MusclePharm Corporation**

**(Exact name of registrant as specified in its charter)**

**NEVADA**  
**(State or other jurisdiction of**  
**incorporation)**

**000-53166**  
**(Commission File Number)**

**77-0664193**  
**(IRS Employer Identification No.)**

**4721 Ironton Street, Building A**

Edgar Filing: MusclePharm Corp - Form 8-K

**Denver, Colorado 80239**

**(Address of principal executive offices) (Zip Code)**

**(303) 396-6100**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;  
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF  
CERTAIN OFFICERS**

On December 30, 2015, MusclePharm Corporation (the Company ) accepted Mr. Richard Estallela s notice to terminate his employment as the Company s President effective immediately. The Company and Mr. Estallela intend to work on a settlement of Mr. Estallela s employment agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MUSCLEPHARM CORPORATION**

Dated: January 6, 2016

By: */s/ Brad J. Pyatt*

Name: Brad J. Pyatt

Title: Chief Executive Officer